Molecular Diagnosis & Therapy

Molecular Diagnosis & Therapy is a bimonthly hybrid journal published by Adis, part of Springer Nature, that has appeared since 1996 and links molecular diagnostics and pharmacogenomics to treatment choice, with a 2025 Journal Impact Factor of 5.8.《分子诊断与治疗》（Molecular Diagnosis & Therapy）由（Adis）出版，隶属（Springer Nature），1996 年创刊，为双月刊、混合开放获取期刊，把分子诊断与药物基因组学同治疗选择相连接，2025 年期刊影响因子为 5.8。

Scope

• Molecular diagnostics for inherited, malignant and infectious disease, including assay development and validation, are central to the journal.遗传病、肿瘤与感染性疾病的分子诊断，包括检测方法的开发与验证，是本刊的核心。
• Companion diagnostics and the co-development of a test with its therapeutic partner are a declared priority.伴随诊断以及检测与其配套治疗方案的协同开发，是期刊明确优先的方向。
• Pharmacogenomics and pharmacogenetic markers of drug response, metabolism, adverse reactions and disease progression are covered.药物反应、代谢、不良反应与疾病进展的药物基因组学与药物遗传学标志物，均在覆盖之列。
• Precision medicine, molecular disease classification and biomarker-guided trial design are treated as one continuum with diagnostics.精准医学、分子疾病分类与生物标志物引导的试验设计，与诊断被视作同一连续体。
• Gene and cell therapies, rare disease testing, nanomedicine and molecular imaging agents appear through original research and review programmes.基因与细胞治疗、罕见病检测、纳米医学与分子影像剂，通过原创研究与综述栏目呈现。
• Ethical, regulatory and health-economic questions raised by molecular testing are explicitly within scope, as are drug approval profiles.分子检测引发的伦理、监管与卫生经济学问题明确属于收稿范围，药物获批概览亦在其中。

History

• The journal was founded in 1996 as Molecular Diagnosis by Adis International in Auckland, New Zealand, and reported on the first wave of polymerase chain reaction based testing.本刊于 1996 年由总部位于新西兰奥克兰的（Adis International）以《分子诊断》（Molecular Diagnosis）之名创办，报道第一波基于聚合酶链反应的检测技术。
• It was retitled Molecular Diagnosis & Therapy from the 2007 volume onwards, as diagnostics and therapeutics came to be developed as pairs rather than separately.自 2007 年卷期起更名为《分子诊断与治疗》，因诊断与治疗日益作为配套而非彼此独立地开发。
• Adis is now part of Springer Nature, and the journal carries the Springer Nature Switzerland copyright line while retaining its Auckland editorial office.（Adis）现隶属（Springer Nature），期刊版权页标注（Springer Nature Switzerland），编辑部仍设于奥克兰。
• It appears six times a year in print and online, with continuous online publication of accepted articles ahead of issue assembly.期刊每年出六期，纸本与在线并行，录用论文在组期前先行在线发表。
• It is a hybrid title, free to authors on the subscription route and open access only where authors choose or funders require it.本刊为混合模式，走订阅路径的作者不付费，仅在作者选择或资助方要求时以开放获取方式发表。
• The 2025 Journal Impact Factor is 5.8, against 4.4 in 2024, 4.476 in 2022 and 4.074 in 2021, placing it in the first quartile of both genetics and pharmacology.2025 年期刊影响因子为 5.8，2024 年为 4.4，2022 年为 4.476，2021 年为 4.074，在遗传学与药理学两个类别中均处第一四分位。

Editors

• Alison Fitches, based at the Adis office in Auckland, is editor-in-chief and is the contact for pre-submission enquiries.常驻奥克兰（Adis）编辑部的 Alison Fitches 任主编，并负责受理投稿前的咨询。
• The editorial board of about thirty members is drawn mainly from North America and Europe, with clinical genetics, laboratory medicine and clinical pharmacology represented in roughly equal measure.约三十人的编委会主要来自北美与欧洲，临床遗传学、检验医学与临床药理学三方面大致均衡。
• Among them are E. Amir of Princess Margaret Cancer Centre in Toronto, G. Bianchi of Vita-Salute San Raffaele in Milan and P. D. Burbelo of the National Institutes of Health.其中包括多伦多玛格丽特公主癌症中心的 E. Amir、米兰圣拉斐尔生命健康大学的 G. Bianchi 以及美国国立卫生研究院的 P. D. Burbelo。
• C. R. Cantor of Boston University, D. L. Cooper of TGen and G. S. Ginsburg of Duke University represent the pharmacogenomic and translational end of the board.波士顿大学的 C. R. Cantor、（TGen）的 D. L. Cooper 与杜克大学的 G. S. Ginsburg 代表编委会中药物基因组学与转化研究的一端。
• Reviews are commissioned and edited in house, and original research is peer reviewed externally, with a median of seven days from submission to first decision.综述由编辑部约稿并自行编辑，原创研究送外部同行评审，投稿至初审中位时间为七天。
• The journal runs standing collections on CRISPR, rare disorders and nanomedicine, and publishes AdisInsight first-approval reports on newly licensed drugs.期刊设有（CRISPR）、罕见病与纳米医学的常设专辑，并刊载（AdisInsight）关于新获批药物的首次批准报告。